Authorities in China have given a green light to an early clinical trial testing inhaled rentosertib for IPF in patients and ...

A constant stream of news, misinformation, and division led columnist Sam Kirton to find ways to reduce the noise — and, in turn, his stress.

Twice a year, columnist Kylene Henderson and her husband, Donnie, make the trek to St. Louis for Donnie's medical ...

Enrollment finished ahead of schedule in a Phase 2 trial testing Calluna Pharma’s experimental CAL101 therapy in adults with ...

Columnist Sam Kirton writes about the passing of a friend with whom he shared a diagnosis of IPF, and reflects on his own patient journey.

A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Bexotegrast, an oral anti-fibrotic treatment candidate from Pliant Therapeutics, is being assessed in a Phase 2b clinical trial in people with idiopathic pulmonary fibrosis (IPF). Called BEACON-IPF, ...

Treatment with the experimental oral therapy GRI-0621 modulated immune cell activity in adults with idiopathic pulmonary fibrosis (IPF) in an early Phase 2a clinical trial, according to new data ...

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan ...